Alzheimer’s Research 2017: Lab-Engineered Molecule Reverses Tau Protein Buildup In Mouse Brains – Medical Daily

Medical DailyAlzheimer’s Research 2017: Lab-Engineered Molecule Reverses Tau Protein Buildup In Mouse BrainsMedical DailyIn the study, injections of the lab-made compound, tau antisense oligonucleotides, into the brains of mice prevented tau from clustering in the brains of young mice and also reversed tau clustering in older mice. In addition, the study reported that …

Read More

New Study Suggests Designer Compound May Treat Alzheimer’s Disease, Other Neurodegenerative Disorders – Scicasts (press release) (blog)

Scicasts (press release) (blog)New Study Suggests Designer Compound May Treat Alzheimer’s Disease, Other Neurodegenerative DisordersScicasts (press release) (blog)The results, published in Science Translational Medicine, suggest that the study of compounds, called tau antisense oligonucleotides, that are genetically engineered to block a cell’s assembly line production of tau, might be pursued as an effective …

Read More

Form 8-K BIO-PATH HOLDINGS INC For: Feb 07 – StreetInsider.com

Form 8-K BIO-PATH HOLDINGS INC For: Feb 07StreetInsider.comHOUSTON—February 7, 2017 – Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today …BIO-PATH HOLDINGS, INC. (NASDAQ:BPTH) Files An 8-K Regulation FD DisclosureMarket Exclusiveall 2 news articles »

Read More

Designer compound may untangle damage leading to some … – National Institutes of Health (press release)

National Institutes of Health (press release)Designer compound may untangle damage leading to some …National Institutes of Health (press release)NIH-funded preclinical study suggests a possible treatment for Alzheimer’s disease and other neurodegenerative disorders.Designer compound may lead to new dementia treatment – UPI.comUPI.comall 2 news articles »

Read More

Designer compound may untangle damage leading to some dementias – EurekAlert (press release)

EurekAlert (press release)Designer compound may untangle damage leading to some dementiasEurekAlert (press release)Currently researchers are conducting early phase clinical trials on the safety and effectiveness of antisense oligonucleotides designed to treat several neurological disorders, including Huntington’s disease and amyotrophic lateral sclerosis. The U.S …and more »

Read More

Bio-Path Holdings to Present at the 19th Annual BIO CEO & Investor Conference – GlobeNewswire (press release)

Bio-Path Holdings to Present at the 19th Annual BIO CEO & Investor ConferenceGlobeNewswire (press release)HOUSTON, Feb. 07, 2017 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer …and more »

Read More

The Zacks: Bio-Path Holdings, Inc. (BPTH) Given $3.25 Average … – DailyQuint

The Zacks: Bio-Path Holdings, Inc. (BPTH) Given $3.25 Average …DailyQuintBio-Path Holdings, Inc. (NASDAQ:BPTH) has been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks …Bio-Path Holdings Inc. (BPTH) Settles Into New 52-Week Low on …Equities.comOne Stock Analysts Are Watching – Bio-Path Holdings (BPTH) – UK …UK Market Newsall 3 news articles »

Read More

Antiviral Therapeutics 2017-2026: Technologies, Markets and Companies – 194 Companies & 174 Collaborations … – Yahoo Finance

Antiviral Therapeutics 2017-2026: Technologies, Markets and Companies – 194 Companies & 174 Collaborations …Yahoo FinanceAdvantages and limitations of delivery of gene-based, antisense and RNAi antiviral therapeutics are discussed. Markets for antivirals are considered according to viruses and diseases caused by them and also according to management approaches: antiviral …and more »

Read More

Research unravels molecular mechanisms of antisense oligonucleotides

Stanley T. Crooke, MD, PhD, CEO of Ionis Pharmaceuticals and recipient of the 2016 Lifetime Achievement Award from the Oligonucleotide Therapeutic Society presents a detailed look at the mechanisms that underlie antisense drug activity in the article entitled “Molecular Mechanisms of Antisense Oligonucleotides,” published in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.

Read More

Antiviral Therapeutics 2017 – Technologies, Markets and Companies – Research and Markets – Yahoo Finance

Antiviral Therapeutics 2017 – Technologies, Markets and Companies – Research and MarketsYahoo FinanceAdvantages and limitations of delivery of gene-based, antisense and RNAi antiviral therapeutics are discussed. Markets for antivirals are considered according to viruses and diseases caused by them and also according to management approaches: antiviral …and more »

Read More

Unraveling the mechanism of antisense oligonucleotides — research from the Crooke Lab – EurekAlert (press release)

EurekAlert (press release)Unraveling the mechanism of antisense oligonucleotides — research from the Crooke LabEurekAlert (press release)Dr. Crooke draws on his extensive experience and long career focused on developing antisense oligonucleotide (ASO) therapeutics and highlights the contributions his group has made over the years to characterizing the three main phases of antisense drug …

Read More

Ionis Earns $5 Million Milestone Payment from Biogen for Advancing a New Program Under Its Broad Neurology … – Military Technologies

Ionis Earns $5 Million Milestone Payment from Biogen for Advancing a New Program Under Its Broad Neurology …Military Technologies„The recent FDA approval of SPINRAZA highlights the potential of our antisense technology to address neurological diseases with high unmet need,” said B. Lynne Parshall, chief operating officer at Ionis. „This latest milestone is one more example of …

Read More

Ionis Earns $5 Million Milestone Payment from Biogen for Advancing a New Program Under Its Broad Neurology … – Yahoo Finance

Ionis Earns $5 Million Milestone Payment from Biogen for Advancing a New Program Under Its Broad Neurology …Yahoo Finance”The recent FDA approval of SPINRAZA highlights the potential of our antisense technology to address neurological diseases with high unmet need,” said B. Lynne Parshall, chief operating officer at Ionis. “This latest milestone is one more example of …and more »

Read More

Isis Pharmaceuticals Inc.: Ionis Pharmaceuticals to Present at Upcoming Investor Conferences – The Wall Street Transcript

Isis Pharmaceuticals Inc.: Ionis Pharmaceuticals to Present at Upcoming Investor ConferencesThe Wall Street TranscriptUsing its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over three dozen drugs in development. SPINRAZA™ (nusinersen) is a drug that has been approved in the U.S. for the treatment …and more »

Read More

Expression of the Antisense-to-Latency Transcript Long Noncoding RNA in Kaposi’s Sarcoma-Associated Herpesvirus – Journal of Virology

Expression of the Antisense-to-Latency Transcript Long Noncoding RNA in Kaposi’s Sarcoma-Associated HerpesvirusJournal of VirologyThe regulation of latency is central to herpesvirus biology. Recent transcriptome-wide surveys have uncovered evidence for promiscuous transcription across the entirety of the Kaposi’s sarcoma-associated herpesvirus (KSHV) genome and postulated the …

Read More

University of Texas Investment Managment Co. Maintains Stake in Bio-Path Holdings, Inc. (BPTH) – Sports Perspectives

University of Texas Investment Managment Co. Maintains Stake in Bio-Path Holdings, Inc. (BPTH)Sports PerspectivesAbout Bio-Path Holdings. Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any …and more »

Read More

Benitec initiates development work on head and neck cancer programs after executing Collaboration Agreement with … – Yahoo Finance

Benitec initiates development work on head and neck cancer programs after executing Collaboration Agreement with …Yahoo FinanceUnder the terms of the executed Research Collaboration Agreement, Benitec has taken control of the clinical development of BB-401, a recombinant DNA construct that produces an antisense RNA with specificity against Epidermal Growth Factor Receptor …and more »

Read More

Scientists develop a Drug likely to benefit people with Alzheimer’s … – http://www.newsgram.com/

http://www.newsgram.com/Scientists develop a Drug likely to benefit people with Alzheimer’s …http://www.newsgram.com/Scientists have developed a drug they hope will benefit people with Alzheimer’s disease, which afflicts an estimated 44 million people around the world.New DNA-Like Drugs Show Promise in Treating Alzheimer’s …Scientific AmericanScientists Discover Way To Reverse Alzheimer’s Symptoms In Mice …International Business Timesall 4 news articles »

Read More

Stocks Alert: Sarepta Therapeutics, Inc. (SRPT), Capstead Mortgage Corporation (CMO), Berry Plastics Group, Inc … – iStreetWire

Stocks Alert: Sarepta Therapeutics, Inc. (SRPT), Capstead Mortgage Corporation (CMO), Berry Plastics Group, Inc …iStreetWireThe company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic …

Read More

New DNA-Like Drugs Show Promise in Treating Alzheimer’s – Scientific American

Scientific AmericanNew DNA-Like Drugs Show Promise in Treating Alzheimer’sScientific AmericanThe findings, reported yesterday in Science Translational Medicine, suggest compounds called antisense oligonucleotides, or ASOs, may not only reduce levels of existing tau but also prevent its formation. ASOs are modified DNA-like molecules designed …Scientists develop a Drug likely to benefit people with Alzheimer’s Diseasehttp://www.newsgram.com/Scientists reverse Alzheimer’s-like symptoms in mice – Malaysia SunMalaysia Sun (press release)New Alzheimer’s drug compound worth investigating, scientists sayJapan TodayTech Times -International Business Timesall 10 news articles »

Read More